55 / 62
•
DDR (DNA Damage Repair) inhibition to increase neoantigen expression and Anti PD1/PD-L1 response
•
PARPs inhibitors
•
CHK1 inhibitors
•
ATR
•
WEE1
•
CAR-T cells targeting CD56 (NCAM) demonstrate preclinical activity
•
Toll-like receptor 9 (TLR9): activate IFN-alpha stimulating monocytes, NK cells, T and NKT cellsCells
•
CD47-bloking immunotherapies stimulate macrophage- mediate destruction of SCLC
•
CDK4/6 inhibition to protect immune cells from chemotherapy-induced cytotoxicity and enhance anti-PD-1/PD-L1
response